Inhibition of the protein kinase mechanistic target of rapamycin (mTOR) with the Food and
Drug Administration (FDA)-approved therapeutic rapamycin promotes health and longevity …

Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults,
with an incidence of over 6500 cases per year in the United States alone. The hallmark of …

Widespread clinical laboratory implementation of next-generation sequencing–based
cancer testing has highlighted the importance and potential benefits of standardizing the …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure
rates exceeding 90% in children, it remains an important cause of morbidity and mortality in …

Background Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is
characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL …

Relapsed and refractory acute lymphoblastic leukemia (ALL) remains difficult to treat, with
minimal improvement in outcomes seen in more than 2 decades despite advances in upfront …

Purpose Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL) is a high-
risk subtype of childhood ALL characterized by kinase-activating alterations that are …

Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk
subtype of ALL in children. There are conflicting data on the incidence and prognosis of Ph …

Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as
BCR-ABL1–like ALL, is a high-risk subset with a gene expression profile that shares …

Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk
subtype characterized by genomic alterations that activate cytokine receptor and kinase …